Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Brand-name drug

Azstarys price, strengths & recalls

Brand of dexmethylphenidate / serdexmethylphenidate (generic)

Pharmacies pay $431.96 for 30 capsules of Azstarys 5.2 mg / 26.1 mg capsule this week, and from $431.96 to $432.44 across its 3 priced strengths and forms. Its official label last changed on May 13, 2026.

Brand
Pharmacies pay$431.96for 30 capsules of 5.2 mg / 26.1 mg capsuleNo change in 4 weeks
Fair cash price
$507.25
Strengths
3
Makers
1
Updated
Nov 11

Azstarys price by strength

What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.

Strength and formPer unitPharmacies pay4 weeks52 weeks
5.2 mg / 26.1 mg capsule Brand$14.40$431.96 / 30 capsulesNo change+3.7%
7.8 mg / 39.2 mg capsule Brand$14.41$432.44 / 30 capsulesNo change+3.8%
10.4 mg / 52.3 mg capsule Brand$14.41$432.41 / 30 capsulesNo change+3.7%

The lowest cost per capsule is 5.2 mg / 26.1 mg capsule at $14.40. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.

Azstarys vs generic dexmethylphenidate / serdexmethylphenidate

There is no generic version of Azstarys on the market yet. Its last listed patent or exclusivity runs to December 9, 2037 - generics often follow, though court cases and settlements can move the date either way.

GenericDexmethylphenidate / serdexmethylphenidate prices

Supply status: shortages & recalls

No shortage reportedChecked Nov 16, 2026
No ongoing recallsNone on record

What did you pay for azstarys? Help the next person.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Official label & what changed

Last changedMay 13, 2026
Version9 of 8
EffectiveMay 11, 2026
Read the label

These highlights do not include all the information needed to use AZSTARYS safely and effectively. See full prescribing information for AZSTARYS. AZSTARYS® (serdexmethylphenidate and dexmethylphenidate) capsules, for oral use, CII Initial U.S. Approval: 2021

This drug has a boxed warning

WARNING: ABUSE, MISUSE, AND ADDICTION

AZSTARYS has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including AZSTARYS, can result in overdose and death [see Overdosage (

10)], and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.

Before prescribing AZSTARYS, assess each patient's risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout AZSTARYS treatment, reassess each patient's risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction [see Warnings and Precautions (

5.1) and Drug Abuse and Dependence (

9.2)].

WARNING: ABUSE, MISUSE, AND ADDICTION

See full prescribing information for complete boxed warning.

AZSTARYS has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including AZSTARYS, can result in overdose and death (

5.1,

9.2,

10):

Before prescribing AZSTARYS, assess each patient's risk for abuse, misuse, and addiction.

Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug.

Throughout treatment, reassess each patient's risk and frequently monitor for signs and symptoms of abuse, misuse, and addiction.

Recent major changes (as listed on the label)

RECENT MAJOR CHANGES

Indications and Usage (

1) 09/2025

Warnings and Precautions (

5.7) 09/2025

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Approval, patents & generics

Application
NDA212994 · Commave Sub
First approved
March 2, 2021 (5 years ago)
Latest approved change
September 23, 2025
Approved label
PDF, Sep 25, 2025
Generic makers
None on the market
Last patent listed
December 9, 2037
Exclusivity ends
May 7, 2026 (ended)

Patent dates are what the maker lists with FDA. Generic launch dates are often set by court rulings or settlements instead. Upcoming generics.

Azstarys questions

How much does azstarys cost without insurance?

Pharmacies pay about $431.96 for 30 capsules of azstarys 5.2 mg / 26.1 mg capsule ($14.40 per capsule). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $507.25. If you're quoted much more, check your quote and ask for the pharmacy's cash price.

Is there a generic for Azstarys?

Yes: dexmethylphenidate / serdexmethylphenidate. Compare dexmethylphenidate / serdexmethylphenidate prices.

Is azstarys in shortage?

No shortage is reported for azstarys right now. We check the national shortage list every day.

Has azstarys been recalled?

No recalls are on record for azstarys.

When did the azstarys label last change?

The official label was last updated on May 13, 2026 (version 9). See what changed.

Talk about azstarys

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.